The US Food and Drug Administration (FDA) has approved avatrombopag (Doptelet, AkaRx Inc) to increase platelet counts in adults with thrombocytopenia and chronic liver disease who are to undergo a ...
The approval of Doptelet was based on results from the ADAPT-1 (N=231) and ADAPT-2 trials (N=204), 2 identically-designed multicenter, randomized, double-blind, placebo-controlled studies. The Food ...
WASHINGTON -- The FDA approved another thrombopoietin receptor agonist on Monday, for an indication not covered by other drugs intended to raise platelet counts. The new agent is avatrombopag ...
Thrombocytopenia (low platelet count) is common in people with cirrhosis. It can be caused by many factors, including an enlarged spleen and decreased platelet production. Severe thrombocytopenia can ...
Patients undergoing transcatheter aortic valve replacement (TAVR) have decreases in platelet counts that are typically transient, lasting just a few days. But in those with preexisting ...
Thrombocytopenia, or a low platelet count, can impair blood clotting, potentially leading to severe bleeding from wounds. Underlying health conditions like autoimmune diseases and cancers, as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback